Ultragenyx Pharmaceutical Inc. RARE
Analyst Consensus
Price Objectif
Analyst historical
| Analyst | Entreprise | Price during analysis | Target price | Potential gain | Publication date |
|---|---|---|---|---|---|
| Ed Arce | H.C. Wainwright | 51.2 $ | 95 $ | 43.80 % | 06/11/2024 |
| Joseph Schwartz | Leerink Partners | 51.2 $ | 85 $ | 33.80 % | 06/11/2024 |
| Salveen Richter | Goldman Sachs | 41.45 $ | 67 $ | 25.55 % | 06/06/2024 |
| Dae Gon Ha | Stifel Nicolaus | 38.65 $ | 127 $ | 88.35 % | 31/05/2024 |
| Christopher Raymond | Raymond James | 38.65 $ | 135 $ | 96.35 % | 31/05/2024 |
| Joel Beatty | Robert W. Baird | 38.65 $ | 72 $ | 33.35 % | 31/05/2024 |
| Whitney Ijem | Canaccord Genuity | 38.65 $ | 111 $ | 72.35 % | 31/05/2024 |
| Dae Gon Ha | Stifel Nicolaus | 42.87 $ | 124 $ | 81.13 % | 15/04/2024 |
| Christopher Raymond | Raymond James | 42.87 $ | 130 $ | 87.13 % | 15/04/2024 |
| Christopher Raymond | Piper Sandler | 51.88 $ | 130 $ | 78.12 % | 28/07/2022 |
| Christopher Raymond | Piper Sandler | 47.7 $ | 135 $ | 87.30 % | 18/05/2022 |
| Yaron Werber | Cowen & Co. | 73.1 $ | 124 $ | 50.90 % | 10/01/2022 |
| Yigal Nochomovitz | Citigroup | 86 $ | 150 $ | 64.00 % | 03/11/2021 |
| Laura Chico | Wedbush | 86 $ | 92 $ | 6.00 % | 03/11/2021 |
| Christopher Raymond | Piper Sandler | 88.66 $ | 170 $ | 81.34 % | 27/09/2021 |
| Esther Rajavelu | UBS | 77.92 $ | 73 $ | -4.92 % | 19/08/2021 |
| Gena Wang | Barclays | 83.77 $ | 141 $ | 57.23 % | 03/08/2021 |